MEGLUDASE for Intravenous Use 1000 General Drug Use-Results Survey (All-case surve )

MEGLUDASE for Intravenous Use 1000 General Drug Use-Results Survey (All-case surve ) - MEGLUDASE for Intravenous Use 1000 General Drug Use-Results Survey (All-case surve )

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240659

Enrollment

Registered

2025-02-03

Start date

2025-01-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxic effects caused by delayed methotrexate excretion due to methotrexate-leucovorin rescue therapy

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received meglutase for detoxification during delayed methotrexate excretion due to methotrexate/leucovorin rescue therapy

Exclusion criteria

Exclusion criteria: Patients with a history of severe hypersensitivity to the components of meglutase

Design outcomes

Primary

Measure	Time frame
Safety(incidence of side effects,etc.)	—

Secondary

Measure	Time frame
Changes in blood methotrexate concentration	—

Contacts

Public ContactOsawa Mitsuharu

OARA Pharmaceutical Co., Ltd.

mitsuharu-osawa@ohara-ch.co.jp+81-3-6740-7701

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026